CAZypedia needs your help! We have many unassigned GH, PL, CE, AA, GT, and CBM pages in need of Authors and Responsible Curators.
Scientists at all career stages, including students, are welcome to contribute to CAZypedia. Read more here, and in the 10th anniversary article in Glycobiology.
New to the CAZy classification? Read this first.
*
Consider attending the 15th Carbohydrate Bioengineering Meeting in Ghent, 5-8 May 2024.
Difference between revisions of "User:Kyle Robinson"
Harry Brumer (talk | contribs) (Created page with "200px|right '''This is an empty template to help you get started with composing your User page.''' You should begin by opening this page for ed...") |
|||
Line 1: | Line 1: | ||
− | [[Image:Blank_user-200px.png|200px|right]] | + | [http://www.example.com link title][[Image:Blank_user-200px.png|200px|right]] |
− | |||
− | + | Kyle Robinson began his studies at [https://en.wikipedia.org/wiki/McGill_University, McGill University], where he completed his B.Sc. while studying under Prof. Paul Wiseman. He has since been pursuing his PhD at the University of British Columbia under the supervision of Prof. [https://www.cazypedia.org/index.php/User:Steve_Withers, Stephen Withers]. His research focuses on the design of selective mechanism-based inhibitors for glycosyl hydrolases, specifically, sialidases and trans-sialidases from [https://www.cazypedia.org/index.php/Glycoside_Hydrolase_Family_33, Family 33]. | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
<!-- Do not remove this Category tag --> | <!-- Do not remove this Category tag --> | ||
[[Category:Contributors|Robinson,Kyle]] | [[Category:Contributors|Robinson,Kyle]] |
Revision as of 13:13, 10 August 2015
Kyle Robinson began his studies at McGill University, where he completed his B.Sc. while studying under Prof. Paul Wiseman. He has since been pursuing his PhD at the University of British Columbia under the supervision of Prof. Stephen Withers. His research focuses on the design of selective mechanism-based inhibitors for glycosyl hydrolases, specifically, sialidases and trans-sialidases from Family 33.